Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Validation of the Oncofetal (OnF) phenotypic reporter

ABSTRACT: Validation of the Oncofetal (OnF) phenotypic reporter

PROVIDER: PRJNA985546 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24967148.fastq.gz	Fastqsanger.gz
	SRR24967149.fastq.gz	Fastqsanger.gz
	SRR24967150.fastq.gz	Fastqsanger.gz
	SRR24967151.fastq.gz	Fastqsanger.gz
	SRR24967152.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Validation of the Oncofetal (OnF) phenotypic reporter

Project description:To test its specificity, VAKSP tumoroids expressing the OnF reporter were sorted based on their GFP expression status. We then performed gene expression profiling analysis using data obtained from mRNA-seq of GFP high and GFP negative VAKPS cells.

2024-10-17 | GSE235205 | GEO

Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer

Project description:Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer

| PRJNA997295 | ENA

Oncofetal reprogramming of the tumor vasculature

Project description:Oncofetal reprogramming of the tumor vasculature

| PRJNA1027431 | ENA

AP-MS with VAR2CSA and oncofetal chondroitin sulfate antibodies

Project description:Tumors display oncofetal chondroitin sulfate (ofCS) glycosaminoglycans that support disease progression and dissemination. ofCS can be detected by the the Plasmodium falciparum derived VAR2CSA protein but the development of recombinant VAR2CSA as a clinical tool has proven challenging. Here, we performed AP-MS experiments with newly developed antibodies with ofCS specificity comparable to VAR2CSA, as well as recombinant VAR2CSA bait.

2024-08-31 | PXD044455 | Pride

Oncofetal reprogramming of the tumor vasculature

Project description:Certain embryonic genes, such as carcinoembryonic antigens (CEA) and oncofetal antigens, become re-expressed in malignant transformation and we hypothesized that a similar phenomenon features tumor endothelial cells as well. Therefore, we performed a systematic search for mouse embryo-specific gene expression at days E11 and E18 in comparison to adult mouse and queried for overexpression of these genes in sorted murine tumor endothelial cells.

2025-04-09 | GSE245218 | GEO

Vaccination against oncofetal targets in the tumor vasculature

Project description:Vaccination against oncofetal targets in the tumor vasculature

| PRJNA1191492 | ENA

Oncofetal gene reactivation drives EZH2-mutant myeloid leukemia pathogenesis

Project description:Oncofetal gene reactivation drives EZH2-mutant myeloid leukemia pathogenesis

| PRJNA725836 | ENA

GNPS Mono-Colonized GF Reporter Mice

Project description:Mono-colonized GF reporter mice fecal metabolomics by LC-MS/MS

2021-08-31 | MSV000088040 | GNPS

Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer.

Project description:Targeting cancer stem cells (CSCs) is crucial for effective cancer treatment, yet resistance mechanisms to LGR5+ CSC depletion in WNT-driven colorectal cancer (CRC) remain elusive. In the present study, we revealed that mutant intestinal stem cells (SCs) depart from their canonical identity, traversing a dynamic phenotypic spectrum. This enhanced plasticity is initiated by oncofetal (OnF) reprogramming, driven by YAP and AP-1, with subsequent AP-1 hyperactivation promoting lineage infidelity. The retinoid X receptor serves as a gatekeeper of OnF reprogramming and its deregulation after adenomatous polyposis coli (APC) loss of function establishes an OnF 'memory' sustained by YAP and AP-1. Notably, the clinical significance of OnF and LGR5+ states in isolation is constrained by their functional redundancy. Although the canonical LGR5+ state is sensitive to the FOLFIRI regimen, an active OnF program correlates with resistance, supporting its role in driving drug-tolerant states. Targeting this program in combination with the current standard of care is pivotal for achieving effective and durable CRC treatment.

| S-EPMC11821538 | biostudies-literature

Monitoring RAS Phenotypic Changes Based on ctDNA to Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer

Project description:Interventions: Gold Standard:Clinical outcome;Index test:RAS phenotypic changes in ctDNA Primary outcome(s): RAS gene phenotype;SEN, SPE, ACC, AUC of ROC Study Design: Sequential

| 2687923 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data